247 related articles for article (PubMed ID: 22810490)
21. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
[TBL] [Abstract][Full Text] [Related]
22. Increased expression of distinct galectins in multiple sclerosis lesions.
Stancic M; van Horssen J; Thijssen VL; Gabius HJ; van der Valk P; Hoekstra D; Baron W
Neuropathol Appl Neurobiol; 2011 Oct; 37(6):654-71. PubMed ID: 21501208
[TBL] [Abstract][Full Text] [Related]
23. Fingolimod for multiple sclerosis.
Pelletier D; Hafler DA
N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
[No Abstract] [Full Text] [Related]
24. Fingolimod in multiple sclerosis: mechanisms of action and clinical efficacy.
Ingwersen J; Aktas O; Kuery P; Kieseier B; Boyko A; Hartung HP
Clin Immunol; 2012 Jan; 142(1):15-24. PubMed ID: 21669553
[TBL] [Abstract][Full Text] [Related]
25. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis.
Kooij G; Mizee MR; van Horssen J; Reijerkerk A; Witte ME; Drexhage JA; van der Pol SM; van Het Hof B; Scheffer G; Scheper R; Dijkstra CD; van der Valk P; de Vries HE
Brain; 2011 Feb; 134(Pt 2):555-70. PubMed ID: 21183485
[TBL] [Abstract][Full Text] [Related]
26. Acid Sphingomyelinase-Derived Ceramide Regulates ICAM-1 Function during T Cell Transmigration across Brain Endothelial Cells.
Lopes Pinheiro MA; Kroon J; Hoogenboezem M; Geerts D; van Het Hof B; van der Pol SM; van Buul JD; de Vries HE
J Immunol; 2016 Jan; 196(1):72-9. PubMed ID: 26597010
[TBL] [Abstract][Full Text] [Related]
27. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
28. Enhanced number and activity of mitochondria in multiple sclerosis lesions.
Witte ME; Bø L; Rodenburg RJ; Belien JA; Musters R; Hazes T; Wintjes LT; Smeitink JA; Geurts JJ; De Vries HE; van der Valk P; van Horssen J
J Pathol; 2009 Oct; 219(2):193-204. PubMed ID: 19591199
[TBL] [Abstract][Full Text] [Related]
29. Sphingolipids: important players in multiple sclerosis.
Halmer R; Walter S; Faßbender K
Cell Physiol Biochem; 2014; 34(1):111-8. PubMed ID: 24977485
[TBL] [Abstract][Full Text] [Related]
30. Statins reduce human blood-brain barrier permeability and restrict leukocyte migration: relevance to multiple sclerosis.
Ifergan I; Wosik K; Cayrol R; Kébir H; Auger C; Bernard M; Bouthillier A; Moumdjian R; Duquette P; Prat A
Ann Neurol; 2006 Jul; 60(1):45-55. PubMed ID: 16729291
[TBL] [Abstract][Full Text] [Related]
31. Ceramide metabolite, not intact ceramide molecule, may be responsible for cellular toxicity.
Tserng KY; Griffin RL
Biochem J; 2004 Jun; 380(Pt 3):715-22. PubMed ID: 14998372
[TBL] [Abstract][Full Text] [Related]
32. Macrophage TNF mRNA expression induced by LPS is regulated by sphingomyelin metabolites.
Lo CJ; Fu M; Lo FR; Cryer HG
Shock; 1999 Jun; 11(6):411-5. PubMed ID: 10454830
[TBL] [Abstract][Full Text] [Related]
33. Roles for HB-EGF and CD9 in multiple sclerosis.
Schenk GJ; Dijkstra S; van het Hof AJ; van der Pol SM; Drexhage JA; van der Valk P; Reijerkerk A; van Horssen J; de Vries HE
Glia; 2013 Nov; 61(11):1890-905. PubMed ID: 24038577
[TBL] [Abstract][Full Text] [Related]
34. Fingolimod for relapsing multiple sclerosis: an update.
Horga A; Castilló J; Montalban X
Expert Opin Pharmacother; 2010 May; 11(7):1183-96. PubMed ID: 20367536
[TBL] [Abstract][Full Text] [Related]
35. The blood-brain barrier in cortical multiple sclerosis lesions.
van Horssen J; Brink BP; de Vries HE; van der Valk P; Bø L
J Neuropathol Exp Neurol; 2007 Apr; 66(4):321-8. PubMed ID: 17413323
[TBL] [Abstract][Full Text] [Related]
36. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Chiba K; Adachi K
Future Med Chem; 2012 Apr; 4(6):771-81. PubMed ID: 22530640
[TBL] [Abstract][Full Text] [Related]
37. Gene expression analysis of the microvascular compartment in multiple sclerosis using laser microdissected blood vessels.
Cunnea P; McMahon J; O'Connell E; Mashayekhi K; Fitzgerald U; McQuaid S
Acta Neuropathol; 2010 May; 119(5):601-15. PubMed ID: 19967542
[TBL] [Abstract][Full Text] [Related]
38. Alterations of calcium homoeostasis in cultured rat astrocytes evoked by bioactive sphingolipids.
Stenovec M; Trkov S; Kreft M; Zorec R
Acta Physiol (Oxf); 2014 Sep; 212(1):49-61. PubMed ID: 24825022
[TBL] [Abstract][Full Text] [Related]
39. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
Huggins A; Sergott RC
Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
[No Abstract] [Full Text] [Related]
40. The effect of FTY720 in the Theiler's virus model of multiple sclerosis.
Li L; Matsumoto M; Seabrook TJ; Cojean C; Brinkman V; Pachner AR
J Neurol Sci; 2011 Sep; 308(1-2):41-8. PubMed ID: 21726878
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
